Yahoo Finance

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Recursion Pharmaceuticals saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on ...
Yahoo Finance

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
The Motley Fool

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Nasdaq

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Nasdaq

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Reuters

Recursion to lay off 20% of workforce amid biotech funding woes

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...